Related Experiment Video
Updated: Jul 31, 2026
11:36
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
22.7K
Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model
M Heidari-Kharaji1, T Taheri1, D Doroud2
1Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.
Parasite Immunology
|May 24, 2016
Summary
Solid lipid nanoparticles (SLN) loaded with paromomycin sulphate (PM-SLN) offer a promising new treatment for leishmaniasis. This formulation enhances drug delivery, improves parasite clearance, and promotes a beneficial immune response.
Area of Science:
- Parasitology
- Nanotechnology
- Immunology
Background:
- Leishmaniasis treatment is challenged by poor drug penetration into infected cells, drug toxicity, and increasing resistance.
- Paromomycin sulphate (PM) shows potential as an antileishmanial drug, but its effectiveness can be improved.
- Solid lipid nanoparticles (SLN) are an effective drug delivery system for colloidal carriers.
Purpose of the Study:
- To develop and evaluate the in vivo efficacy of paromomycin sulphate loaded solid lipid nanoparticles (PM-SLN) against Leishmania major.
- To assess the therapeutic potential of PM-SLN in a mouse model of leishmaniasis.
Main Methods:
- PM was encapsulated into SLN to create PM-SLN.
- In vivo efficacy was tested in Leishmania (L.) major-infected BALB/c mice.
- Footpad swelling, parasite load (real-time PCR), cytokine levels (IL-4, IFN-γ), and nitric oxide were evaluated.
Main Results:
- PM-SLN formulation demonstrated safety in vivo.
- PM-SLN effectively reduced parasite load and footpad swelling in infected mice.
- Treatment with PM-SLN promoted a shift towards a Th1 immune response, indicated by increased IFN-γ levels.
Conclusions:
- PM-SLN is a safe and effective formulation for treating leishmaniasis.
- SLN enhances the antileishmanial efficacy of paromomycin sulphate.
- The PM-SLN formulation improves drug delivery and modulates the host immune response favorably.
Related Concept Videos
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...